Lopez-Cortes Johanna Valentina, Acin-Martinez Sergio, Montoya Guillermo, Balcazar Norman
Facultad Barberi de Ingeniería, Diseño y Ciencias Aplicadas, Departamento de Ciencias Farmacéuticas, Biomédicas y Veterinarias, Universidad Icesi, Valle Del Cauca, Cali 760031, Colombia.
Facultad de Medicina, Universidad de Antioquia, Antioquia, Medellín 050010, Colombia.
Adv Pharmacol Pharm Sci. 2025 Aug 24;2025:4687213. doi: 10.1155/adpp/4687213. eCollection 2025.
Type 2 diabetes mellitus is closely linked with obesity and associated metabolic dysfunctions, including insulin resistance, dyslipidemia, and chronic inflammation. Pentacyclic triterpene acids (PTAs) derived from are promising bioactive compounds that may help mitigate these disorders. This study investigated the effects of a PTA-rich fraction on metabolic disruptions in cellular and diet-induced obesity mouse models. Prediabetic C57BL/6J mice fed on high-fat diet (HFD) for 8 weeks exhibited typical metabolic abnormalities, such as increased body weight, glucose intolerance, hyperinsulinemia, and dyslipidemia, which served as a baseline for assessing PTA efficacy. 8-week treatment with PTAs showed significant improvement in glucose metabolism, enhancing insulin sensitivity and glucose tolerance and reducing plasma insulin levels. Although PTAs did not alter body weight or lipid profiles in HFD-fed mice in a sacha inchi oil (SIO) vehicle, they effectively prevented further weight gain, especially with intraperitoneal administration. Interestingly, we found that SIO, used as PTA solubilizer, yielded similar hypoglycemic and anti-inflammatory outcomes, and coadministration did not yield additive or synergistic effects. Furthermore, both PTAs and SIO demonstrated in vitro anti-inflammatory activity by downregulating proinflammatory gene expression, and no adverse liver, kidney, and pancreas toxicity was observed. In conclusion, PTAs from and SIO present potential as nontoxic, bioactive agents for modulating carbohydrate metabolism and inflammation in obesity-related conditions, although further studies are warranted to optimize dosing and investigate SIO's standalone therapeutic potential.
2型糖尿病与肥胖及相关代谢功能障碍密切相关，包括胰岛素抵抗、血脂异常和慢性炎症。源自[具体来源未给出]的五环三萜酸（PTAs）是有前景的生物活性化合物，可能有助于缓解这些疾病。本研究调查了富含PTA的组分对细胞和饮食诱导的肥胖小鼠模型中代谢紊乱的影响。以高脂饮食（HFD）喂养8周的糖尿病前期C57BL/6J小鼠表现出典型的代谢异常，如体重增加、葡萄糖不耐受、高胰岛素血症和血脂异常，这些作为评估PTA疗效的基线。用PTAs治疗8周显示葡萄糖代谢有显著改善，增强了胰岛素敏感性和葡萄糖耐受性，并降低了血浆胰岛素水平。尽管在以印加果油（SIO）为载体的HFD喂养小鼠中，PTAs未改变体重或血脂谱，但它们有效地防止了进一步的体重增加，尤其是腹腔注射时。有趣的是，我们发现用作PTA增溶剂的SIO产生了类似的降血糖和抗炎结果，联合给药未产生相加或协同作用。此外，PTAs和SIO均通过下调促炎基因表达表现出体外抗炎活性，且未观察到肝脏、肾脏和胰腺的不良毒性。总之，来自[具体来源未给出]的PTAs和SIO具有作为无毒生物活性剂调节肥胖相关病症中碳水化合物代谢和炎症的潜力，尽管需要进一步研究以优化剂量并研究SIO的独立治疗潜力。
